Related Experiment Videos
[Nephrotic syndrome refractory to conventional therapy].
E Ragazzoni1, S Agliata, G Airoldi
1Divisione di Nefrologia e Dialisi, Ospedale, Borgomanero.
Summary
Cyclosporin A (CyA) effectively reduces proteinuria in Nephrotic Syndrome (NS) patients resistant to conventional therapy. This immunosuppressant offers significant antiproteinuric benefits, improving overall patient health markers.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Nephrotic Syndrome (NS) typically treated with prednisone and immunosuppressants.
- Steroid-resistant or relapsing NS cases may require alternative therapies.
- Cyclosporin A (CyA) shows potential due to its immunomodulatory and antiproteinuric effects.
Purpose of the Study:
- To assess the antiproteinuric effectiveness of Cyclosporin A (CyA) in patients with Nephrotic Syndrome (NS) refractory to standard treatments.
Main Methods:
- A cohort of six patients (3 male, 3 female) received CyA at 4 +/- 0.5 mg/Kg/day.
- Treatment was combined with low-dose corticosteroid therapy.
Main Results:
- Proteinuria decreased by over two-thirds in 5 out of 6 patients.
- Biochemical improvements included increased total proteinemia and reduced cholesterolemia and triglyceridemia.
- Renal function (creatinine) and blood pressure remained stable throughout treatment.
Conclusions:
- Four patients maintained therapy for extended periods (2-30 months).
- Two patients discontinued CyA; one achieved sustained remission, while another experienced relapse post-pregnancy.
- CyA demonstrates significant antiproteinuric efficacy in refractory NS, with manageable side effects.